Departments of Small Animal Medicine & Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
Vet Comp Oncol. 2012 Dec;10(4):283-91. doi: 10.1111/j.1476-5829.2011.00295.x. Epub 2011 Oct 17.
Treatment of feline vaccine-associated sarcoma (VAS) is challenging, in part due to the high likelihood of tumour recurrence despite aggressive local therapy. Lomustine is potentially an attractive agent to add to the current treatment armamentarium. In this de-escalating phase I/II prospective trial, 28 cats with measurable VAS were treated at target dosages of 38-60 mg m(-2) every 3 weeks until disease progression. The overall response rate was 25%, with a median progression-free survival and median duration of response of 60.5 and 82.5 days, respectively. Haematologic toxicity, specifically cumulative neutropenia, was significant, and dose reductions and treatment delays were common. Although these data support further investigation of lomustine for the treatment of VAS, safe, multidosing protocols must first be determined.
治疗猫疫苗相关性肉瘤（VAS）具有挑战性，部分原因是尽管采用了积极的局部治疗，但肿瘤仍极有可能复发。洛莫司汀有可能成为目前治疗手段的一个有吸引力的添加物。在这项逐步降低剂量的 I/II 期前瞻性试验中，28 只可测量的 VAS 猫以 38-60mg/m²的目标剂量每 3 周接受治疗，直到疾病进展。总缓解率为 25%，无进展生存期和缓解持续时间的中位数分别为 60.5 和 82.5 天。血液学毒性，特别是累积中性粒细胞减少症，很显著，剂量减少和治疗延迟很常见。尽管这些数据支持进一步研究洛莫司汀治疗 VAS，但必须首先确定安全的多剂量方案。
